Paper Details

  1. Home
  2. Paper Details

Adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in advanced previously treated breast cancer: an ECOG pilot study.

Author: TaylorS G, WolterJ

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the effectiveness of a combination of adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in 9 patients with advanced breast cancer who had failed prior chemotherapy. The combination was terminated early due to severe neurotoxicity, hematologic toxicity, and gastrointestinal side effects.
Paper Details　
Original Abstract of the Article :
A combination of adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine was piloted in patients with advanced breast cancer who had failed prior CMFP chemotherapy, as a part of ongoing trials by the Eastern Cooperative Oncology Group to improve second-line chemotherapy for this disease. Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/mpo.2950090213

データ提供：米国国立医学図書館（NLM）

A Pilot Study Evaluating Adriamycin, Vincristine, Dibromodulcitol, and Hexamethylmelamine for Advanced Breast Cancer

This study takes us into the world of oncology, specifically exploring the effectiveness of a combination chemotherapy regimen for advanced breast cancer. Researchers conducted a pilot study to evaluate the efficacy of a combination of Adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in patients with advanced breast cancer who had failed prior chemotherapy. They aimed to assess the potential benefits and toxicities of this treatment approach.

Limited Therapeutic Benefit and Severe Toxicity

The study found that the combination chemotherapy regimen resulted in severe neurotoxicity and other side effects, leading to early termination of the trial. While some patients showed a temporary response to the treatment, the overall therapeutic benefit did not outweigh the toxicity. This highlights the need for careful consideration of the balance between efficacy and toxicity in cancer treatment.

Navigating the Complexities of Cancer Treatment

This study underscores the challenges of finding effective and safe treatments for advanced cancer. It emphasizes the importance of carefully evaluating the risks and benefits of each treatment option, particularly in cases where patients have experienced previous treatment failures. Just as a desert traveler must weigh the risks and rewards of each path, healthcare professionals must navigate the complex landscape of cancer treatment with careful consideration.

Dr.Camel's Conclusion

This pilot study serves as a reminder of the complexities of cancer treatment. It highlights the ongoing search for effective and safe therapies while emphasizing the importance of balancing efficacy with toxicity. Just as a desert explorer faces constant challenges and setbacks, cancer researchers persevere in their quest for better treatments, offering hope for a healthier future for cancer patients.

Date :
  1. Date Completed 1981-07-09
  2. Date Revised 2019-09-04
Further Info :

Pubmed ID

6785566

DOI: Digital Object Identifier

10.1002/mpo.2950090213

Related Literature

Article Analysis
・Side Effects of altretamine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.